Halozyme Therapeutics, Inc. $HALO Shares Purchased by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 46.2% in the second quarter, Holdings Channel reports. The firm owned 16,506 shares of the biopharmaceutical company’s stock after acquiring an additional 5,214 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Halozyme Therapeutics were worth $859,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Isthmus Partners LLC increased its position in Halozyme Therapeutics by 2.5% during the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC increased its position in Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares in the last quarter. Park Place Capital Corp increased its position in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares in the last quarter. Xponance Inc. increased its position in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after purchasing an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other news, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at $1,840,207.26. This trade represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 108,227 shares of company stock worth $7,779,595. 2.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HALO shares. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a research report on Tuesday, October 14th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price objective for the company. Finally, Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $73.00.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $67.03 on Monday. The stock has a market cap of $7.84 billion, a P/E ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a 50 day moving average of $71.56 and a 200-day moving average of $62.09. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business’s revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.